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lopidogrel Pharmacogenomics: Next Steps
Clinical Algorithm, Gene–Gene Interactions, and an Elusive Outcomes Trial
atrick Gladding, MBCHB,*§ Laura Panattoni, PHD,† Mark Webster, MBCHB,‡
eslie Cho, MD,* Stephen Ellis, MD*
leveland, Ohio; and Auckland, New Zealand
lopidogrel pharmacogenomics has received signiﬁcant attention since a black box warning was an-
ounced by the Food and Drug Administration in March. This has left clinicians in a difﬁcult situation
here many questions remain unanswered. In this brief viewpoint article, we ask some pointed ques-
ions of our own and outline the pathway that needs to be taken for clinical translation to occur.
J Am Coll Cardiol Intv 2010;3:995–1000) © 2010 by the American College of Cardiology Foundationb
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cn March 12, 2010, the U.S. Food and Drug
dministration (FDA) released a black box warn-
ng on the antiplatelet drug clopidogrel (1). This
arning alerted clinicians of the heterogeneity of
esponse to clopidogrel and advised pharmacoge-
etic testing with consideration of alternative an-
iplatelet agents in nonresponders. This elicited a
trong reaction from clinicians as no prospective
andomized trial has shown that this treatment
trategy improves clinical outcomes. Clinical trials
esting this hypothesis are underway, but several
uestions remain to be answered. One unaddressed
uestion is why this has not been explored further
y pharmaceutical companies involved with clopi-
ogrel manufacture. It is common practice that
harmaceutical compounds are screened at an early
tage against cytochrome P450 enzymes. This
ssesses whether a drug is metabolized by polymor-
hic cytochrome P450 enzymes (i.e., pathways that
re known to vary markedly in a population).
ompounds that are metabolized by a single path-
ay are generally discontinued from further devel-
pment. Although this knowledge might not have
rom the *Cleveland Clinic, Cleveland, Ohio; †School of Population
ealth, University of Auckland, Auckland, New Zealand; ‡Green Lane,
ardiovascular Service, Auckland City Hospital, Auckland, New Zeal-
nd; and the §Theranostics Laboratory, Auckland, New Zealand. Drs.
ladding and Webster have a patent pending regarding clopidogrel
harmacogenomics, and Dr. Gladding has founded a nonprofit com-
any, Theranostics Laboratory. All other authors have reported that they
ave no relationships to disclose.(
anuscript received June 4, 2010; revised manuscript received August
4, 2010, accepted August 25, 2010.een available for clopidogrel during its early de-
elopment, it does not preclude laboratory work
eing done in phase IV post-marketing surveil-
ance. Eli Lilly and Company first reported a
enetic basis to the response to clopidogrel in 2006
2) and has continued to investigate this. However,
o attempt was made to explore this finding by
ther pharmaceutical companies involved with the
icensing or sales of clopidogrel. Because of these
ndings, a biomarker program was built into the
hase I/II trials of the Lilly drug development
rogram for prasugrel. The subsequent TRITON
TRial to Assess Improvement in Therapeutic
utcomes by Optimizing Platelet InhibitioN with
rasugrel) (3) had a genomic component that
howed that the CYP2C19*2 polymorphism con-
erred a risk to carriers taking clopidogrel but not
o those receiving prasugrel (4). This result sup-
orted the earlier strong scientific evidence of in
ivo and ex vivo experiments showing the impor-
ance of the CYP2C19 gene and enzyme in clopi-
ogrel metabolism (5–9). Despite this finding, in 1
f the largest pharmacogenetic trials performed,
he message of using genetic testing has not been
art of Lilly’s marketing strategy.
The FDA decision overall, however, is not
ompletely unexpected. The FDA Critical Path
nitiative has long supported the role of pharma-
ogenomics in drug development and views it as a
athway to improving patient responses to medi-
ation and reducing the cost of drug development
10). In assessing new treatments the FDA uses
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996dvanced population modeling tools, such as pharmacomet-
ics, which assesses the impact of polymorphic variability in
population (1,11). From a population basis, there is an
rgument that individualizing treatment will not only ben-
fit patients but also save money for health care providers. In
ountries such as New Zealand and Germany, where clo-
idogrel is generic and inexpensive, there stands a clear
dvantage of targeting expensive agents to nonresponders.
ith a Monte Carlo simulation, we have modeled the
ost-effectiveness of using pharmacogenomics to target
igh-risk patients for treatment with prasugrel (12). Al-
hough our method did not include clinical risk factors or
latelet testing, genomics alone was sufficient to target
ubpopulations in a cost-effective manner. The reason this is
f importance to the providers of health care resources is
hat clopidogrel is the second-most-prescribed drug in the
orld, with global sales of over $6 billion. There will soon
e a generic version of clopidogrel in many countries which
ill substantially reduce that cost (13). However, substitut-
ng clopidogrel for a new patented medication will lead to
ngoing cost, for the duration of that patent life. Of further
nterest in our cost-effectiveness study was the result that
thnic groups, with a higher frequency of the CYP2C19*2
allele, benefited the most from a
targeted strategy. In the U.S.,
African Americans and Asians
carry this single nucleotide poly-
morphism (SNP) at a dispropor-
tionately higher rate than Cau-
casians (3). The cost of testing in
our simulation was modeled at
175 and needs to be performed once in a lifetime. This
akes it unattractive to industries that benefit from repeated
iagnostic testing (12).
Table 1. Clinical Outcome Studies Evaluating CYP2C19*2
First Author (Ref. #) n, Trial Name Clopidogrel Dose
Shuldiner et al. (16) n  429 300/75 mg
Mega et al. (2) n  1,477
TRITON
300/75 mg
Simon et al. (17) n  2,208
FAST-MI
300/75 mg
Collet et al. (18) n  259 75 mg
Sibbing et al. (19) n  2,485 600/75 mg
Giusti et al. (20) n  772 600/75 mg
Trenk et al. (21) n  797 600/75 mg
ADP platelet function using ADP agonist; CI confidence interval; CV cardiovascular; FAST-MI
bbreviations
nd Acronyms
DA  Food and Drug
dministration
NP  single nucleotide
olymorphismevent; ST stent thrombosis; TRITON TRial to Assess Improvement in Therapeutic Outcomes by OptimizThe black box decision of the FDA was based on a
umber of clinical trials and meta-analyses but also on a
ponsor-funded trial of 40 healthy volunteers (Table 1)
2,14–21). These volunteers received 75 mg and 150 mg of
lopidogrel in a crossover study, with platelet function as an
utcome, and showed that a marginal benefit was obtained
n dose escalation (1). Although alternative antiplatelet
reatments were recommended in the warning, specific
gents were not mentioned, leaving clinicians with minimal
uidance on what to do next. Several recent studies have
nvestigated the benefits of alternative treatments for non-
esponders, but these have focused on platelet function to
uide treatment strategies (22–25). Of concern is that
omparative outcome studies have shown that only a small
andful of platelet function analyzers actually predict events.
efinitions of nonresponse with these functional tests are
lso often lacking. Despite these disadvantages, it seems
ttractive to test the pharmacodynamic outcome, that is,
hat the drug does to the body. Although recent studies
ave suggested that platelet function testing outperforms
enotyping, the pharmacogenomics of clopidogrel is not yet
ully elucidated (26,27). The known CYP2C19 polymor-
hisms are thought to only contribute 12% to 20% of
esponse variability, and it seems evident that other genes
re involved (28). The result from a recent genome-wide
ssociation study has shown that the response to clopidogrel
s highly heritable (70%) (16). Because CYP2C19*2 only
xplains 12% to 20% of variability, it is probable that other
enes or rare variants within the 2C19 gene will explain this
igh heritability. There are a number of further factors to
onsider with the CYP2C19 gene. First, each individual
arries 2 copies of the gene, CYP2C19*2 heterozygotes still
ave 1 functional copy and this means that a higher dose of
lopidogrel might be effective. However, with saturable
Clinical Outcome Risk for CYP2C19*2 Carriers
V event or death HR: 2.42 (95% CI: 1.18–4.99; p  0.02)
ACE
T
AR between *2 carriers vs. Wt  4.1%
HR: 1.5 (95% CI: 1.07–2.2, p  0.01)
HR: 3.09 (95% CI: 1.19–8.00, p  0.02)
ACE HR: 1.98 (95% CI: 1.10–3.58, p  0.05)
ACE  death
T
HR: 3.69 (95% CI: 1.69–8.05, p  0.0005)
HR: 6.02 (95% CI: 1.81–20.04, p  0.0009)
T HR: 3.81 (95% CI: 1.45–10.02, p  0.007)
Wt/Wt HR: 0.4%
*2/Wt HR: 1.5%
*2/*2 HR: 2.1%
V death OR: 2.7 (95% CI: 1.00–8.42, p  0.05)
(ADP) OR: 2.9 (95% CI: 1.08–12.98, p  0.08)
(*2/Wt)  ADP 11.45 (95% CI: 1.84–71.27, p  0.009)
ortality OR: 3.0 (95% CI: 1.4–6.8; p  0.004)
try on Acute ST–ElevationMyocardial Infarction; HR hazard ratio; MACEmajor adverse cardiacC
M
S
M
M
S
S
C
M
 Regising Platelet InhibitioN with Prasugrel; Wtwild type.
e
T
n
a
w
e
V
C
v
a
n
b
g
h
d
t
n
C
a
t
i
r
e
e
a
f
C
m
a
f
a
a
s
t
(
a
s
p
r
a
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 1 0 , 2 0 1 0 Gladding et al.
O C T O B E R 2 0 1 0 : 9 9 5 – 1 0 0 0 Clopidogrel Pharmacogenomics: Next Steps
997nzyme kinetics means this benefit might be marginal (22).
he CYP2C19*2 homozygotes, with 2 null alleles, might
ot respond to higher doses and might require an alternative
ntiplatelet drug (19).
The field of pharmacogenomics is rich with examples
here multiple interacting genes act in combination to influ-
nce drug response. Warfarin response is influenced by the
KORC1, CYP2C9, GGCX, and CYP4F2 genes (29–31).
lopidogrel absorption and metabolism is complex and in-
olves multiple biological bottlenecks, essentially efflux pumps
nd enzymes that have polymorphic genes. Biological bottle-
ecks are prone to significant influence from outside pertur-
ations and are particularly affected by “multiple hits.” The
enes for each step in clopidogrel absorption and metabolism
ave already been well-characterized (Fig. 1), and new evi-
ence is emerging that testing other SNPs—such as a SNP in
he ABCB1 gene—in addition to CYP2C19*2 identifies more
onresponders (32).
Looking at the oncology literature is also helpful as
YP2C19 is involved with the response to some chemother-
peutics. The science here is more evolved and shows that
Figure 1. Antiplatelet Drug Clopidogrel Pathway
Genes are shown in blue ovals. Adapted, with permission, from PharmGKB an
Clopidogrel pathway. Pharmacogenet Genomics 2010;20:463–5.he gene is induced by inflammatory disease states and
nfluenced by master gene regulators. The main master
egulator is the human pregnane receptor gene, which also
ffects CYP3A4 (33–35). The inducible nature of gene
xpression for 2C19 and the multifactorial nature of platelet
ctivation and aggregation argue for the addition of platelet
unction testing in personalizing antiplatelet treatment.
linical context and timing are vitally important in deter-
ining the correct treatment for patients. Platelets are
ctivated by a number of agonists, and many platelet
unction assays measure global responses, influenced by
dditional factors, such as acutely generated thrombin that
re not influenced by antiplatelet agents. Therefore it makes
ense that testing both genetic factors and platelet aggrega-
ion will yield more information than testing either alone
Fig. 2) (20). Platelet reactivity is higher around the time of
n acute coronary syndrome, and this might explain the
hort-term benefits of prasugrel in acute coronary syndrome
atients. Stratifying a patient to a long-term treatment
egimen, when platelet reactivity is elevated during this
cute period is nonintuitive. A practical situation worth
ford University–Sangkuhl K, Klein TE, Altman RB.d Stan
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998onsidering is the individual who has already been treated
ith a potent irreversible antiplatelet agent, or efficacious
gent with a long half-life, (i.e., prasugrel or glycoprotein
Ib/IIIa inhibitor, respectively). In this circumstance it is
ot possible to identify responders to clopidogrel with
unctional testing. Genotyping in this circumstance is a
ogical option. Possible strategies that incorporate pharma-
ogenomics and platelet testing include the possibility of
sing platelet testing at the point of discharge or after discharge
o modify treatment in the clinic. In addition to measuring
rug efficacy, outpatient functional testing would provide an
bjective measure of compliance. The combination of testing
enotype and phenotype has been valuable, in other examples
f clinical pharmacogenomics. Thiopurine methyltransferase
enotyping, for gastroenterology patients on azathioprine, is an
xample. Recommendations for this drug include initial geno-
yping, treatment stratification and subsequent phenotypic
esting to monitor hematological dyscrasia (36).
Clinicians are reserved about incorporating genotyping
nto clinical practice for a number of reasons. Lack of
linical trial evidence is perhaps the first issue, which might
oon be resolved. A therapeutic window for antiplatelet
rugs is sorely needed, and early demonstration of such a
oly grail is alluring (37). Integrating multiple factors
nvolved in drug response is also necessary. An algorithm for
lopidogrel pharmacogenomic nonresponse has already
een formulated by a group in Germany, though this
equires validation in independent cohorts and use in a
CYP2C19 gene
Master Gene Regulators 
e.g. hPXR
Cytokines e.g. IL-6, TNFα
Patient Phenotype
e.g. CVA, age, weight,
C
Multiplex 
cytokine 
analysis
Pharmacogenomics
Figure 2. Hypothesized Systems Approach to Clopidogrel Response
Larger font items indicate important components in the system. Green font it
response. Reprinted, with permission, from Gladding et al. (22). ABCB1  p-gly
pregnane X receptor; IL  interleukin; TNF  tumor necrosis factor; T2DM  trospective trial (Fig. 3) (38). Arguing that complexity will cimit the clinical applicability of an algorithm undervalues
he power of electronic medical records with decision
upport and electronic prescribing tools. Cost, reimburse-
ent, and availability of testing are often raised as concerns;
owever, testing is available through a number of providers
rom both large laboratories and genotyping platform pro-
iders. Although costs of $400 are quoted with turnaround
imes of 1 week, the cost of testing can be provided at
ubstantially less than this, with turnaround times of 2 to
h (22). The Nanosphere Verigene and Autogenomics
NFINITI genotyping platforms are examples. A final point
orth making is that financial incentives and the directions
n which they bias treatment need to be addressed. Person-
lized medicine is not popular with industries that benefit
rom a 1-sizes-fits-all business strategy. However, individ-
alization of drug treatment should be considered no
ifferent from stent sizing for a stenotic lesion, or choice of
drug-eluting stent based on lesion or patient profile. Is it
ustifiable to perform intravascular ultrasound or optical
oherence tomography but not genotyping/phenotyping for
rug treatment? These questions need addressing in cost-
ffectiveness and comparative effectiveness studies. Current
edical practice of providing all options to patients, without
nowledge of their benefits, is not sustainable. Current
ractice will need to be replaced with a health care system
elivered with greater refinement, targeted use of resources,
nd the ability to compare and monitor outcomes. Given
he increasing complexity and volume of information in
CYP2C19 enzyme
Drug-drug 
interactions
betes
-gene interactions
e.g ABCB1
Platelet
P2Y12 gene
Metabolomics
Functional testing
Active metabolite
Prodrug
Gut absorption
e.g. CES
dicate other forms of testing which may be valuable in assessing drug
tein efﬂux pump; CES  carboxylesterase; CVA  stroke; hPXR  human
diabetes; wt  weight. dia
YP
ems in
coprolinical medicine, software tools will need to be developed
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999hat use clinical trial information to assist in decision
upport in this new model of health care. Simulations of
linical trials and outcomes for an individual are likely to
ecome increasingly valuable.
A recent survey in Nature Reviews: Drug Discovery reported
hat between 40% and 80% of all early-stage pharmaceutical
ompounds have biomarker programs running alongside drug
evelopment, which serve to tailor drug response (39). Many
ncology drugs are now available with companion diagnostics,
hich allow clinicians to target treatment. As we enter the era
f personalized medicine, it is probable that more drugs will
nter the cardiovascular field with companion diagnostics,
therwise known as theranostics. Mass customization has
ade its way into many aspects of our lives and proven itself to
e an effective means of minimizing cost and wastage. Clini-
ians will need to be prepared for this change in practice, which
s no longer just around the corner—it is already here.
eprint requests and correspondence: Dr. Patrick Gladding,
leveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195.
-mail: gladdip@ccf.org.
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Authors suggest use of clinical risk fac
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viii. ABCB1 C3435T efflux
1) Calculate Score:
7 = prasugrel 60/10 mg,
<7 = clopidogrel 600/75 mg
(Exclusions to prasugrel age 75 year
2) Platelet Testing:
Reassign treatment based on platelet
misclassification based on genotype a
*Not based on clinical trial evidence or
authors take no responsibility for use o
and recommend that this strategy be t
trial. Integration of a bleeding risk scor
required for optimization of this strateg
Figure 3. Pharmacogenomic Algorithm
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